Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells

Clin Cancer Res. 2003 Oct 1;9(12):4376-86.

Abstract

Purpose: Breast cancers are known to frequently (over)express several well-characterized tumor-associated antigens (TAAs) such as carcinoembryonic antigen, MUC-1, Her-2/neu, and cancer/testis antigens such as NY-ESO-1, SSX-2, and members of the MAGE family. Whereas in melanoma patients, the detection of pre-existing T cell responses to tumor-associated differentiation antigens was a rationale to initiate several vaccination strategies, little is known thus far concerning tumor-specific immunity in breast cancer patients. The objectives of our study were (a) to modify and compare different immunodiagnostic T cell assays with regard to their suitability for clinical applications and (b) to determine endogenous TAA-specific T cell immunity of breast cancer patients at the time point of primary diagnosis.

Experimental design: Using MUC-1- and Her-2/neu-derived HLA-A*0201-restricted peptides as model antigens, we analyzed antigen-dependent IFN-gamma release of T cells by enzyme-linked immunospot (ELISpot) assay, intracellular cytokine flow cytometry (CytoSpot), and quantitative real-time PCR. As an assay independent of T cell function, we performed tetramer staining.

Results: In our hands, the quantitative real-time PCR method is most sensitive and a feasible screening test to perform an "immunological staging" of cancer patients. By doing this, we detected in 7 of 13 (54%) of HLA-A*0201(+) breast cancer patients a pre-existent specific cellular immune response to at least one of the investigated TAAs (MUC-1, Her-2/neu, carcinoembryonic antigen, NY-ESO-1, and SSX-2). Four of 21 patients (19%) were found to have a significant Her-2/neu-specific T cell response as defined by a stimulation index >/==" BORDER="0"> 2 (range, 10-88).

Conclusions: Although the clinical relevance of endogenous TAA-specific immunity remains unclear, our findings suggest that patients with primary breast cancer can mount a T cell immune response to their tumor that might be beneficially enhanced by TAA-dependent vaccination strategies in the adjuvant situation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigen-Presenting Cells
  • Antigens, Neoplasm / genetics
  • Antigens, Neoplasm / immunology*
  • Breast Neoplasms / immunology*
  • Carcinoembryonic Antigen / genetics
  • Carcinoembryonic Antigen / immunology
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Gene Expression Regulation, Neoplastic
  • HLA-A Antigens / immunology
  • HLA-A2 Antigen
  • Humans
  • Immunity, Cellular
  • Interferon-gamma / metabolism
  • Leukocytes, Mononuclear / immunology
  • Membrane Proteins / genetics
  • Membrane Proteins / immunology
  • Mucin-1 / genetics
  • Mucin-1 / immunology
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / immunology
  • Neoplasm Staging
  • Peptide Fragments / immunology
  • Receptor, ErbB-2 / genetics
  • Receptor, ErbB-2 / immunology
  • Repressor Proteins / genetics
  • Repressor Proteins / immunology
  • Reverse Transcriptase Polymerase Chain Reaction
  • T-Lymphocytes / immunology*

Substances

  • Antigens, Neoplasm
  • CTAG1B protein, human
  • Carcinoembryonic Antigen
  • HLA-A Antigens
  • HLA-A*02:01 antigen
  • HLA-A2 Antigen
  • Membrane Proteins
  • Mucin-1
  • Neoplasm Proteins
  • Peptide Fragments
  • Repressor Proteins
  • synovial sarcoma X breakpoint proteins
  • Interferon-gamma
  • Receptor, ErbB-2